Semaglutide (Ozempic/Wegovy)

Semaglutide, marketed as Ozempic and Wegovy, is a prescription medication that helps manage type 2 diabetes and aids in weight loss by mimicking the hormone GLP-1. In a large primary care dataset study published in Pharmacoepidemiol Drug Saf in 2025, researchers documented the use of compounded GLP-1 receptor agonists, including semaglutide, and found that these medications were widely prescribed for both diabetes management and weight loss. The study also noted that semaglutide was associated with significant improvements in glycemic control and weight reduction, though it highlighted the importance of monitoring side effects such as gastrointestinal issues.

Semaglutide connects to other nodes related to type 2 diabetes management, weight loss strategies, and GLP-1 receptor agonists. It is also linked to discussions on the safety and efficacy of compounded medications in primary care settings. The evidence from this single study provides a foundation for understanding semaglutide's role in clinical practice, but more research is needed to fully assess long-term outcomes and broader population impacts.

Sources

• Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. (PMID:41024632)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._